OBJECTIVE: To identify gaps in therapy with urate-lowering drugs for the treatment of gout as well as factors associated with resuming therapy. METHODS: From 2 integrated delivery systems, we identified patients 18 years or older with a diagnosis of gout who initiated use of a urate-lowering drug from January 1, 2000 through June 30, 2006 and who had a gap in therapy. A gap was defined as a period of over 60 days after the completion of 1 prescription in which no refill for a urate-lowering drug was obtained. Survival curves were used to assess return to therapy of urate-lowering drugs. Cox proportional hazards analysis estimated the association between covariates and return to therapy. RESULTS: There were 4166 new users of urate-lowering drugs (97% received allopurinol), of whom 2929 (70%) had a gap in therapy. Among those with a gap, in 75% it occurred in the first year of therapy. Fifty percent of patients with a gap returned to therapy within 8 months, and by 4 years it was 75%. Age 45-74 years (<45 referent) and greater duration of urate-lowering drug use before the gap was associated with resuming treatment within 1 year. In contrast, receipt of nonsteroidal anti-inflammatory drugs or glucocorticoids in the year before the gap was associated with a reduced likelihood of resuming therapy. CONCLUSIONS: The majority of gout patients with gaps in urate-lowering drug use returned to treatment. More investigation is needed to better understand why patients may go for months without refilling prescriptions, given the clinical consequences of nonadherence. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVE: To identify gaps in therapy with urate-lowering drugs for the treatment of gout as well as factors associated with resuming therapy. METHODS: From 2 integrated delivery systems, we identified patients 18 years or older with a diagnosis of gout who initiated use of a urate-lowering drug from January 1, 2000 through June 30, 2006 and who had a gap in therapy. A gap was defined as a period of over 60 days after the completion of 1 prescription in which no refill for a urate-lowering drug was obtained. Survival curves were used to assess return to therapy of urate-lowering drugs. Cox proportional hazards analysis estimated the association between covariates and return to therapy. RESULTS: There were 4166 new users of urate-lowering drugs (97% received allopurinol), of whom 2929 (70%) had a gap in therapy. Among those with a gap, in 75% it occurred in the first year of therapy. Fifty percent of patients with a gap returned to therapy within 8 months, and by 4 years it was 75%. Age 45-74 years (<45 referent) and greater duration of urate-lowering drug use before the gap was associated with resuming treatment within 1 year. In contrast, receipt of nonsteroidal anti-inflammatory drugs or glucocorticoids in the year before the gap was associated with a reduced likelihood of resuming therapy. CONCLUSIONS: The majority of goutpatients with gaps in urate-lowering drug use returned to treatment. More investigation is needed to better understand why patients may go for months without refilling prescriptions, given the clinical consequences of nonadherence. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Boris L G van Wijk; Jerry Avorn; Daniel H Solomon; Olaf H Klungel; Eibert R Heerdink; Anthonius de Boer; Alan M Brookhart Journal: J Hypertens Date: 2007-03 Impact factor: 4.844
Authors: M Alan Brookhart; Amanda R Patrick; Sebastian Schneeweiss; Jerry Avorn; Colin Dormuth; William Shrank; Boris L G van Wijk; Suzanne M Cadarette; Claire F Canning; Daniel H Solomon Journal: Arch Intern Med Date: 2007-04-23
Authors: Chaitanya A Sarawate; Kathleen K Brewer; Wenya Yang; Pankaj A Patel; H Ralph Schumacher; Kenneth G Saag; Alan W Bakst Journal: Mayo Clin Proc Date: 2006-07 Impact factor: 7.616
Authors: W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska Journal: Ann Rheum Dis Date: 2006-05-17 Impact factor: 19.103
Authors: M Alan Brookhart; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; Amanda R Patrick; Helen Mogun; Daniel H Solmon Journal: Am J Med Date: 2007-03 Impact factor: 4.965
Authors: Leslie R Harrold; Kathleen M Mazor; Daniel Peterson; Nausheen Naz; Cassandra Firneno; Robert A Yood Journal: BMC Musculoskelet Disord Date: 2012-09-21 Impact factor: 2.362
Authors: Samantha S R Crossfield; Lana Yin Hui Lai; Sarah R Kingsbury; Paul Baxter; Owen Johnson; Philip G Conaghan; Mar Pujades-Rodriguez Journal: PLoS One Date: 2019-10-24 Impact factor: 3.240
Authors: Jane C Richardson; Jennifer Liddle; Christian D Mallen; Edward Roddy; Samantha Hider; Suman Prinjha; Sue Ziebland Journal: BMC Musculoskelet Disord Date: 2016-06-06 Impact factor: 2.362